Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Synaptic inhibition is essential for shaping the dynamics of neuronal networks, and aberrant inhibition plays an important role in neurological disorders. Gephyrin is a central player at inhibitory postsynapses, directly binds and organizes GABAA and glycine receptors (GABAARs and GlyRs), and is thereby indispensable for normal inhibitory neurotransmission. Additionally, gephyrin catalyzes the synthesis of the molybdenum cofactor (MoCo) in peripheral tissue. We identified a de novo missense mutation (G375D) in the gephyrin gene (GPHN) in a patient with epileptic encephalopathy resembling Dravet syndrome. Although stably expressed and correctly folded, gephyrin-G375D was non-synaptically localized in neurons and acted dominant-negatively on the clustering of wild-type gephyrin leading to a marked decrease in GABAAR surface expression and GABAergic signaling. We identified a decreased binding affinity between gephyrin-G375D and the receptors, suggesting that Gly375 is essential for gephyrin-receptor complex formation. Surprisingly, gephyrin-G375D was also unable to synthesize MoCo and activate MoCo-dependent enzymes. Thus, we describe a missense mutation that affects both functions of gephyrin and suggest that the identified defect at GABAergic synapses is the mechanism underlying the patient's severe phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Heterozygous dominant negative GPHN variants cause DEEs 115 and biallelic LOF variants with EIMFS 116 , confirming the role of gephyrin in maintaining inhibitory signalling in the brain.”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [115]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 60 · Cited by 49
Metadata
- Authors
- Dejanovic, B., Djémié, T., Grünewald, N., Suls, A., Kress, V., Hetsch, F., Craiu, D., Zemel, M., Gormley, P., Lal, D., EuroEPINOMICS Dravet working group, Myers, C. T., Mefford, H. C., Palotie, A., Helbig, I., Meier, J. C., De Jonghe, P., Weckhuysen, S., & Schwarz, G.
- Affiliations
- University of Cologne (DE)
- University of Antwerp (BE)
- Technische Universität Braunschweig (DE)
- Carol Davila University of Medicine and Pharmacy (RO)
- University of Washington (US)
- Harvard University (US)
- Broad Institute (US)
- Children's Hospital of Philadelphia (US)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Dejanovic, Borislav
- Weckhuysen, Sarah
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2015-11-27
- Volume
- 7
- Issue
- 12
- Pages
- 1580-1594
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC4693503
- OpenAlex
- W2179389164
- Cited by
- 49
- References
- 60
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 7 · 2017: 4 · 2016: 4
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-12-01)
- Open access
- gold
- doi.org
- Licence
- other-oa
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- German Science Foundation (DFG SFB635)
- Investissements d'avenir (ANR‐10‐IAIHU‐06)
- Wellcome Trust (089062, 098051)
- European Commission Framework Programme 7 (FP7) projects (Synsys‐242167, gEUVADIS‐261123)
- Academy of Finland (251704, 263401)
- Sigrid Juselius Foundation
- US NIH (HL113315)
- Eurocores program EuroEPINOMICS of the European Science Foundation
- Fund for Scientific Research Flanders
- University of Antwerp
- Bundesministerium für Bildung und Forschung BMBF
- Deutsche Forschungsgemeinschaft DFG Priority Programme (ME2075/7‐1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- gephyrin, epileptic encephalopathy, Dravet syndrome, GABAergic synapses, GABAA receptor, glycine receptor, synaptic inhibition, dominant negative effect, receptor clustering, GABAergic neurotransmission
- MeSH terms
- Molybdenum Cofactors, Carrier Proteins, Coenzymes, Epilepsy, Humans, Membrane Proteins, Metalloproteins, Pteridines, Receptors, GABA-A, Synapses, Mutation, Missense
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy. https://app.cochat.ai/papers/10.15252/emmm.201505323
- The paper
- Dejanovic, B., Djémié, T., Grünewald, N., Suls, A., Kress, V., Hetsch, F., Craiu, D., Zemel, M., Gormley, P., Lal, D., EuroEPINOMICS Dravet working group, Myers, C. T., Mefford, H. C., Palotie, A., Helbig, I., Meier, J. C., De Jonghe, P., Weckhuysen, S., & Schwarz, G. (2015). Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201505323
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.